The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

An experimental drug shows promise as an effective new approach for treating multiple sclerosis and the intestinal ailment Crohn's disease. In preliminary tests, the new drug Antegren dramatically ...

Find Therapeutics secured CA$10 million in funding to continue advancing tasronetide, its treatment to restore damaged myelin ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...

A breakthrough in stem cell research has provided a glimmer of hope for a new treatment that could halt the development of multiple sclerosis, researchers have said. A clinical study found injecting ...

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

Expert Rev Neurother. 2010;10(5):791-809. As of 9 February 2010, 35 cases of progressive multifocal leukoencephalopathy (PML) were diagnosed in more than 64,000 patients having received natalizumab ...